Advertisement
Home »

Treatment of severe acute necrotizing encephalopathy of childhood with interleukin-6 receptor blockade in the first 24 h as add-on immunotherapy shows favorable long-term outcome at 2 years.

Mar 27, 2023

ABOUT THE EXPERTS

  • Patrick H Hosie

    Department of Neurology, Sydney Children’s Hospital, Randwick, Australia.

    Carylyn Lim

    Rehab2Kids, Sydney Children’s Hospital, Randwick, Australia.

    Timothy R D Scott

    Rehab2Kids, Sydney Children’s Hospital, Randwick, Australia; Discipline of Pediatrics and Child Health, School of Clinical Medicine, UNSW Medicine and Health, UNSW Sydney, Australia; Graduate School of Biomedical Engineering, UNSW Sydney, Australia.

    Michael Cardamone

    Department of Neurology, Sydney Children’s Hospital, Randwick, Australia; Discipline of Pediatrics and Child Health, School of Clinical Medicine, UNSW Medicine and Health, UNSW Sydney, Australia.

    Michelle A Farrar

    Department of Neurology, Sydney Children’s Hospital, Randwick, Australia; Discipline of Pediatrics and Child Health, School of Clinical Medicine, UNSW Medicine and Health, UNSW Sydney, Australia.

    Catherine Frith

    Department of Immunology and Infectious Diseases, Sydney Children’s Hospital, Randwick, Australia.

    Peter I Andrews

    Department of Neurology, Sydney Children’s Hospital, Randwick, Australia.

    Jason Pinner

    Centre for Clinical Genetics, Sydney Children’s Hospital, Randwick, Australia.

    Sekhar Pillai

    Department of Neurology, Sydney Children’s Hospital, Randwick, Australia; Discipline of Pediatrics and Child Health, School of Clinical Medicine, UNSW Medicine and Health, UNSW Sydney, Australia. Electronic address: sekhar.pillai@health.nsw.gov.au.

REFERENCES & ADDITIONAL READING

PubMed

MORE ARTICLES BELOW

PW Weekly Newsletters

The latest articles and insights from your colleagues in your specialty(ies) of choice.


Advertisement
Advertisement
ad
ad
MORE ARTICLES BELOW

PW Weekly Newsletters

The latest articles and insights from your colleagues in your specialty(ies) of choice.

SUBSCRIBE NOW

View all newsletters

Advertisement